According to Cipla, its Sereflo fluticasone/salmeterol MDI, a generic version of Advair (Seretide), has been approved by the UK MHRA for the treatment of asthma, and the product will be launched by a partner in the UK within a few weeks.
Cipla Ltd. Global CEO Umang Vohra commented, “We are extremely pleased with the approval of Sereflo in the UK. This is a testament of Cipla’s relentless efforts in the respiratory field for over a decade. This reinforces Cipla’s commitment to make a difference in the life of patients with its innovative products. Sereflo will help patients with moderate to severe asthma breathe better.”
Read the Cipla press release.
